Skip to main content
. 2024 Feb 21;9(4):102254. doi: 10.1016/j.esmoop.2024.102254

Figure 2.

Figure 2

Increased proliferation in T cell subsets following treatment with retifanlimab. Fold-change in the frequency of proliferating (Ki67+) cells in different T-cell subsets (left panel: CD3+/CD8+; center panel: CD3+/CD4+; right panel: CD3+/CD4+/CD25+/FoxP3+). Analysis included 28 patients enrolled in the tumor-specific cohorts receiving retifanlimab 3 mg/kg q2w. ∗P < 0.05 by Wilcoxon matched pairs test with each time point compared with C1D1. C1D1, cycle 1 day 1; FC, fold change; q2w, every 2 weeks; Treg cells, regulatory T cells.